Constantin Ioana Luciana Badila, Dima Vlad, Zaharie Corina Gabriela
Ovidius University, Faculty of Medicine, Constanta, Romania.
"St. Andrei" County Clinical Emergency Hospital of Constanta, Romania.
Maedica (Bucur). 2025 Mar;20(1):90-98. doi: 10.26574/maedica.2025.20.1.90.
As neonatal intensive care has developed, there has been a growing focus on reducing mortality and morbidity. Hypoxic-ischemic injury remains the primary cause of neonatal brain dysfunction. Recently, notable advancements have been made in neuroprotection, particularly with the introduction of therapeutic hypothermia. Furthermore, identifying specific biomarkers has constituted another significant advance in neuroprotection, allowing clinicians to screen infants for brain injury, monitor disease progression, identify affected regions and assess the efficacy of neuroprotective trials. Erythropoietin (EPO) has demonstrated potential in the treatment of perinatal hypoxia, particularly in the reduction of neurological damage and improvement of outcomes in neonates with hypoxic-ischemic encephalopathy. While further research is required to ascertain the optimal usage, the existing evidence suggests that EPO could be a valuable component of a comprehensive treatment plan, potentially in conjunction with therapeutic hypothermia.
随着新生儿重症监护的发展，人们越来越关注降低死亡率和发病率。缺氧缺血性损伤仍然是新生儿脑功能障碍的主要原因。最近，神经保护方面取得了显著进展，特别是治疗性低温的引入。此外，识别特定生物标志物是神经保护的另一项重大进展，使临床医生能够对婴儿进行脑损伤筛查、监测疾病进展、确定受影响区域并评估神经保护试验的疗效。促红细胞生成素（EPO）已显示出治疗围产期缺氧的潜力，特别是在减少神经损伤和改善缺氧缺血性脑病新生儿的预后方面。虽然需要进一步研究以确定最佳用法，但现有证据表明，EPO可能是综合治疗方案的一个有价值的组成部分，可能与治疗性低温联合使用。
